Dr. Scott M. Rocklage, PhD is an entrepreneur based in the Boston, MA. His journey in the healthcare field is expansive. Dr. Rocklage joined 5AM Ventures in 2003 and rose to leadership in 2004 as a managing partner; his resume continued and continues to grow.
He served various roles on the board of numerous pharmaceuticals businesses such as Relapse, Novira, and Rennovia. He was Chairman and CEO of Cubist Pharmaceuticals and President and CEO of Nycombed Salutar.
Dr. Rocklage’s company, 5AM Ventures, is a life venture capital firm. It is a science-based company that creates and forms other business in the field of science.
The company works with scientist and other business professionals; helping them to turn their ideas in to businesses that produce medicine for medical needs that are not being met. Studies in different medical conditions, such as cancer, are leading to improvements in medicines that extend and saves lives.
Dr. Rocklage received his Bachelors of Science and his PhD in Chemistry from University of California, Berkeley and Massachusetts Institute of Technology. While attending MIT Rocklage conducted research in the laboratory of 2005 noble prize winner Richard R. Schrock. Learn more about Scott Rocklage: http://chemistry.mit.edu/scott-rocklage-phd-2-and-his-wife-patty-are-celebrated-their-major-gift and http://www.rennovia.com/team/scott-m-rocklage/
With more than three decades of management experience in the healthcare field, Dr. Scott Rocklage was able to utilize his leadership role to get the FDA to approve three new drug applications in the U.S. for Omniscan, Teslascan, and Cubicin.
Dr. Rocklage has also been able to enter some of his new drugs into clinical trials. He has invented and co-invented more than thirty U.S. patens and has written over 100 peer-reviewed publications.